Shopping Cart
- Remove All
Your shopping cart is currently empty
PR-Set7 Protein, Human, Recombinant
Catalog No. TMPY-01584
KMT5A (known as PR-Set7/9, SETD8 and SET8), a member of the SET domain containing methyltransferase family specifically targeting H4K20 for methylation, has been implicated in multiple biological processes. Inhibition of KMT5A attenuated proliferation and induced apoptosis. Elevated KMT5A expression was significantly correlated with extrathyroidal extension, lymph node metastasis and advanced pathological stage of papillary thyroid cancer. KMT5A may be a novel oncogenic factor, specifically a regulator for lipid metabolism in papillary thyroid carcinoma.
PR-Set7 Protein, Human, Recombinant
Catalog No. TMPY-01584
KMT5A (known as PR-Set7/9, SETD8 and SET8), a member of the SET domain containing methyltransferase family specifically targeting H4K20 for methylation, has been implicated in multiple biological processes. Inhibition of KMT5A attenuated proliferation and induced apoptosis. Elevated KMT5A expression was significantly correlated with extrathyroidal extension, lymph node metastasis and advanced pathological stage of papillary thyroid cancer. KMT5A may be a novel oncogenic factor, specifically a regulator for lipid metabolism in papillary thyroid carcinoma.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 100 μg | $600 | 7-10 days |
Bulk & Custom
Add to Cart
Resource Download
Product Information
| Biological Activity | Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first. |
| Description | KMT5A (known as PR-Set7/9, SETD8 and SET8), a member of the SET domain containing methyltransferase family specifically targeting H4K20 for methylation, has been implicated in multiple biological processes. Inhibition of KMT5A attenuated proliferation and induced apoptosis. Elevated KMT5A expression was significantly correlated with extrathyroidal extension, lymph node metastasis and advanced pathological stage of papillary thyroid cancer. KMT5A may be a novel oncogenic factor, specifically a regulator for lipid metabolism in papillary thyroid carcinoma. |
| Species | Human |
| Expression System | E. coli |
| Tag | Tag Free |
| Accession Number | Q9NQR1-2 |
| Synonyms | SET8,SET07,SET domain containing (lysine methyltransferase) 8,PR-Set7,KMT5A |
| Construction | A DNA sequence encoding the human SETD8 (NP_065115.3) (Lys 195-His 352) was expressed and purified, with two additional amino acids (Gly & Pro) at the N-terminus. Predicted N terminal: Gly |
| Protein Purity | > 98 % as determined by SDS-PAGE |
| Molecular Weight | 18.2 kDa (predicted); 18 kDa (reducing conditions) |
| Endotoxin | Please contact us for more information. |
| Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing 20 mM Tris, 100 mM NaCl, pH 8.0.Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization. |
| Reconstitution | A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information. |
| Stability & Storage | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
| Shipping | In general, Lyophilized powders are shipping with blue ice. |
| Research Background | KMT5A (known as PR-Set7/9, SETD8 and SET8), a member of the SET domain containing methyltransferase family specifically targeting H4K20 for methylation, has been implicated in multiple biological processes. Inhibition of KMT5A attenuated proliferation and induced apoptosis. Elevated KMT5A expression was significantly correlated with extrathyroidal extension, lymph node metastasis and advanced pathological stage of papillary thyroid cancer. KMT5A may be a novel oncogenic factor, specifically a regulator for lipid metabolism in papillary thyroid carcinoma. |
Dose Conversion
You can also refer to dose conversion for different animals. More
Calculator
Tech Support
Please read the User Guide of Recombinant Proteins for more specific information.
Preview
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.